Paper Details

  1. Home
  2. Paper Details

Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.

Author: BresslerLinda, DeSimoneJoseph, DornLouise, KoshyMabel, LavelleDonald, MolokieRobert, TalischyNasrin

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

This study investigates the effect of repeated decitabine dosing on HbF levels and hematologic toxicity in patients with sickle cell anemia. Decitabine effectively increased HbF levels without significant cumulative toxicity.
Paper Details　
Original Abstract of the Article :
We have previously demonstrated that 5-aza-2'-deoxycytidine (decitabine) augments fetal hemoglobin (HbF) levels in patients with sickle cell anemia (SS) who did not respond to hydroxyurea (HU). The present study was designed to determine the effect of repeated decitabine dosing on HbF levels and hem...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/12010787

データ提供：米国国立医学図書館（NLM）

Decitabine: A Promising Treatment for Sickle Cell Anemia

Sickle cell anemia is a serious genetic blood disorder that affects red blood cells, leading to chronic pain, fatigue, and other complications. While hydroxyurea (HU) is currently the standard treatment, not all patients respond to it, prompting the search for alternative therapies. This study explored the potential of decitabine, a drug known to increase fetal hemoglobin (HbF) levels, as a treatment option for sickle cell anemia patients who don't respond to HU.

A New Hope for Sickle Cell Anemia Patients

The researchers administered decitabine to seven patients with sickle cell anemia, including five who had not responded to HU. They found that repeated decitabine dosing effectively increased HbF levels without causing significant side effects or toxicity. The average HbF levels increased from 3.12% to 13.93% during the 9-month treatment period. The study also noted an increase in hemoglobin (Hb) levels, indicating improved overall blood health.

Improving Quality of Life for Sickle Cell Anemia Patients

This research highlights the potential of decitabine as a viable treatment option for patients with sickle cell anemia who don't respond to HU. By increasing HbF levels, decitabine may help alleviate some of the symptoms and complications associated with this disease, improving patients' quality of life. However, further research is needed to determine the long-term effects of decitabine treatment and to refine the optimal dosing regimen.

Dr. Camel's Conclusion

The findings of this study are like a refreshing oasis in the desert for sickle cell anemia patients. Decitabine offers a potential solution for those who don't respond to current treatments, providing hope for a better future. Like a determined camel traversing a vast expanse, researchers are continuing to explore new avenues for treating sickle cell anemia, seeking to bring relief and improve the lives of those affected by this challenging disease.

Date :
  1. Date Completed 2002-07-01
  2. Date Revised 2021-02-16
Further Info :

Pubmed ID

12010787

DOI: Digital Object Identifier

S0006-4971(20)60758-3

Related Literature

Article Analysis
・Effects of decitabine injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.